ArticleBMC surgery2025
Nomograms based on SIRI for predicting postoperative survival outcomes in patients with non-metastatic clear cell renal cell carcinoma.
Article in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Clinicopathological features and prognostic factors associated with long-term survival (≥5 years) in patients with clear cell renal cell carcinoma and venous tumor thrombus].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- Specific diagnostic value of systemic immune-inflammation indices combined with nutritional and tumor markers in the stage diagnosis of pancreatic cancer: a retrospective cohort study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the prognostic significance of the preoperative Systemic Inflammation Response Index (SIRI) and to develop predictive models for overall survival (OS), cancer specific survival (CSS), and metastasis free survival (MFS) in patients with non-metastatic clear cell renal cell carcinoma (ccRCC) after nephrectomy.
methodsWe conducted a retrospective analysis of clinicopathological and prognostic data from 231 non-metastatic ccRCC patients. The optimal cutoff value for SIRI was determined using receiver operating characteristic (ROC) curve analysis. Prognostic factors were identified through least absolute shrinkage and selection operator (LASSO) regression and multivariable Cox proportional hazards models. Nomograms for predicting OS, CSS, and MFS were constructed based on selected predictors. The performance of the nomograms was evaluated using time-dependent ROC curves, time-dependent concordance index (C- index), calibration plots, and decision curve analysis (DCA). The predictive efficacy of our nomograms was compared with that of established models.
resultsAmong 231 patients, 21 (9.1%) died including 17 (7.4%) ccRCC-specific deaths; 32 (13.9%) developed postoperative metastases. An elevated SIRI (> 1.405) was independently associated with worse survival outcomes. Multivariable Cox analysis confirmed SIRI as an independent predictor of OS, CSS, and MFS. Nomograms integrating SIRI with other clinicopathological variables were successfully developed. Time dependent ROC curves and C - index demonstrated superior predictive performance of the nomogram compared to conventional clinicopathological characteristics. Calibration plots showed strong agreement between predicted and observed outcomes, and DCA confirmed high clinical utility. Our nomograms outperformed the established Stage, Size, Grade, and Necrosis (SSIGN) score and University of California Los Angeles Integrated Staging System (UISS) models in predictive accuracy.
conclusionsElevated pretreatment SIRI independently predicts reduced OS, CSS, and MFS in non-metastatic ccRCC patients. The developed nomograms, which incorporate SIRI and key with clinicopathological characteristics, demonstrate excellent predictive performence, and serve as valuable tools for prognostic assessment in the management of patients with non-metastatic ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.